echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Marizomib orphan drug qualification approved

    Marizomib orphan drug qualification approved

    • Last Update: 2014-03-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: China Science Daily March 6, 2014 triphase accelerator announced that its new drug marizomib has obtained the orphan drug qualification granted by the FDA orphan drug research and development office Marizomib is a powerful proteasome inhibitor for the treatment of multiple myeloma As a result, triphase can obtain a 7-year exclusive period and other benefits "We are pleased that the FDA has awarded marizomib orphan drug qualification for the treatment of multiple myeloma patients." Frank stonebanks, founder, chairman and CEO of triphase, said, "although patients with refractory multiple myeloma have a longer life span and improved quality of life after drug treatment, they still need a new treatment plan We are very excited to see the excellent therapeutic effect of marizomib We hope that marizomib can improve the traditional treatment mode and transform the treatment of acute diseases into the treatment of chronic controllable diseases "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.